Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.050
-0.200 (-4.71%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Zentalis Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2018
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2018
Market Capitalization
287872161,0721,1493,808
Upgrade
Market Cap Growth
254.01%-59.52%-79.86%-6.72%-69.82%80.54%
Upgrade
Enterprise Value
81-153-1326017753,443
Upgrade
Last Close Price
4.051.353.0315.1520.1484.06
Upgrade
PS Ratio
--3.20---
Upgrade
PB Ratio
1.290.400.642.452.6510.45
Upgrade
P/TBV Ratio
1.330.400.642.472.6710.57
Upgrade
Debt / Equity Ratio
0.180.180.130.110.110.13
Upgrade
Net Debt / Equity Ratio
-0.95-0.95-0.97-1.00-0.90-0.81
Upgrade
Net Debt / EBITDA Ratio
1.471.471.761.771.731.42
Upgrade
Net Debt / FCF Ratio
1.651.651.922.102.351.84
Upgrade
Asset Turnover
--0.14---
Upgrade
Quick Ratio
6.736.737.136.967.727.74
Upgrade
Current Ratio
6.936.937.327.167.987.98
Upgrade
Return on Equity (ROE)
-49.54%-49.54%-42.83%-67.09%-59.39%-47.60%
Upgrade
Return on Assets (ROA)
-24.48%-24.48%-23.86%-28.53%-28.59%-31.67%
Upgrade
Return on Capital Employed (ROCE)
-55.80%-55.80%-49.60%-51.60%-47.10%-50.60%
Upgrade
Earnings Yield
-47.71%-156.79%-76.80%-27.25%-20.60%-4.17%
Upgrade
FCF Yield
-43.60%-143.28%-79.23%-19.44%-14.47%-4.21%
Upgrade
Buyback Yield / Dilution
-1.11%-1.11%-8.67%-23.75%-23.82%-51.84%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.